Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)

Study acronym: PELFIRE
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title shortened, about 2 wordsv2
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amsterdam UMC, location VUmc
78 trials monitored
See 3 trials at risk
Lung Cancer
4,803 trials monitored
See 272 trials at risk
Colorectal Cancer
3,410 trials monitored
See 164 trials at risk
Prostate Cancer
2,555 trials monitored
See 170 trials at risk
and 4 more diseases
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.
Trial Details
NCT Number NCT07782164
Lead Sponsor Amsterdam UMC, location VUmc
Conditions
(from sponsor)		 Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer (Including Metastatic Cancer), Anal Cancer +1 more
Related terms Anus Neoplasms, Colorectal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Recurrence, Local, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov